Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt A. Herberts III sold 16,630 shares of Sangamo Therapeutics stock in a transaction on Friday, December 1st. The stock was sold at an average price of $16.13, for a total transaction of $268,241.90. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Sangamo Therapeutics, Inc. (SGMO) opened at $16.65 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64. Sangamo Therapeutics, Inc. has a one year low of $2.65 and a one year high of $18.40.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. The company had revenue of $11.81 million for the quarter, compared to analysts’ expectations of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. Sangamo Therapeutics’s revenue for the quarter was up 333.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.27) EPS. research analysts forecast that Sangamo Therapeutics, Inc. will post -0.73 earnings per share for the current year.

Several brokerages have recently weighed in on SGMO. ValuEngine upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Piper Jaffray Companies set a $8.00 target price on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Friday, August 18th. Jefferies Group restated a “buy” rating and set a $18.00 target price on shares of Sangamo Therapeutics in a research note on Friday, October 13th. Finally, Barclays began coverage on shares of Sangamo Therapeutics in a research note on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $17.83.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Sangamo Therapeutics by 12.4% in the 2nd quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock valued at $30,551,000 after acquiring an additional 384,031 shares during the last quarter. State Street Corp increased its holdings in Sangamo Therapeutics by 51.6% in the 2nd quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock valued at $16,441,000 after acquiring an additional 636,296 shares during the last quarter. RA Capital Management LLC bought a new stake in Sangamo Therapeutics in the 2nd quarter valued at $11,000,000. Northern Trust Corp increased its holdings in Sangamo Therapeutics by 4.9% in the 2nd quarter. Northern Trust Corp now owns 947,832 shares of the biopharmaceutical company’s stock valued at $8,341,000 after acquiring an additional 44,656 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in Sangamo Therapeutics by 93.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 693,300 shares of the biopharmaceutical company’s stock valued at $10,400,000 after acquiring an additional 335,595 shares during the last quarter. Institutional investors own 64.35% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Sangamo Therapeutics, Inc. (SGMO) VP Curt A. Herberts III Sells 16,630 Shares of Stock” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/sangamo-therapeutics-inc-sgmo-vp-curt-a-herberts-iii-sells-16630-shares-of-stock/1744703.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.